**WEB PAGE:** Clinical Trials [NEW]\_v1d1

Regional Cancer Care Associates – Central Jersey

**URL:**

www. https://centraljerseyrcca.com/services/clinical-trials/

**Title** (characters = 58):

Breakthrough Cancer Care via Clinical Trials in New Jersey

**Description** (characters = 156):

Clinical trials are how tomorrow’s cancer (and hematology) treatments are investigated today. And they’re how RCCA-CJD gives new hope to Central New Jersey.

**ABOVE SECTION FOR INTERNAL USE ONLY** – Please exclude from client review

# Volunteer for a Clinical Trial with RCCA-CJ for Access to Breakthrough Cancer Care

At Regional Cancer Care Associates Central Jersey, we’re committed to providing you or your loved one real hope against cancer. And clinical trials are an important part of this commitment.

By participating in a variety of clinical trials, we’re able to offer you breakthrough alternative therapies when other treatments haven’t proven effective at fighting your cancer.

## We’re investigating tomorrow treatments today.

If you or someone you love is being treated for cancer without success, clinical trials can offer new hope. Clinical trials are how all treatments are investigated for their safety and effectiveness. As such, every treatment in use today was first studied through clinical trials, and the first people helped by any treatment were those who participated in the clinical trial.

At RCCA Central Jersey, you have access to the advanced clinical trials and leading-edge sophistication you might expect only from large, bustling metropolitan cancer treatment centers, but right here close to home. What’s more, we participate in trials where we are the only community-based participant or just one of a small handful in the United States.

At the same time, we are dedicated to your or your loved one’s safety and to restoring your hope for treatment success

## Clinical Trials at RCCA Central Jersey Currently Accepting New Patients

Here are the studies currently being led by RCCA Central Jersey and its specialists:

|  |  |
| --- | --- |
| **Phase** | 2 |
| **Title** | [A Phase 2 Study of Lisocabtaqgene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients with Aggressive B-cell NHL (TRANSCEND-PILOT-017006)](https://clinicaltrials.gov/ct2/show/NCT03483103?term=NCT03483103&draw=2&rank=1) |

|  |  |
| --- | --- |
| **Phase** | 2 |
| **Title** | [A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting](https://clinicaltrials.gov/ct2/show/NCT03744676?term=NCT03744676&draw=2&rank=1) |

|  |  |
| --- | --- |
| **Phase** | 1b |
| **Title** | [A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors](https://clinicaltrials.gov/ct2/show/NCT03181100?term=NCT03181100&draw=2&rank=1) |

|  |  |
| --- | --- |
| **Phase** | 1b |
| **Title** | [A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Rucaparib in Patients With Advanced Breast, Ovarian, or Prostate Cancer](https://clinicaltrials.gov/ct2/results?cond=&term=bo40933&cntry=&state=&city=&dist=&Search=Search) |

|  |  |
| --- | --- |
| **Phase** | 2 |
| **Title** | [A Phase II, Single-arm Trial to Investigate Tepotinib in Advanced ( Stage IIIB/IV) Non-small Cell Lung Cancer With MET-exon-14 (METex14) Skipping Alterations or MET Amplification (VISION)](https://clinicaltrials.gov/ct2/show/NCT02864992?term=MS200095-0022&draw=2&rank=1) |

|  |  |
| --- | --- |
| **Phase** | 3 |
| **Title** | [VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)](https://clinicaltrials.gov/ct2/show/NCT03511664?term=psma-617-01&draw=2&rank=1) |

|  |  |
| --- | --- |
| **Phase** | Non-interventional |
| **Title** | An Exploratory Biomarker Study of Checkpoint Inhibitors (PD-1, PD-L1 and CTLA-4) used as Monotherapy or In Combination In Patients with Cancer |

*This study was not provided with a URL*

|  |  |
| --- | --- |
| **Phase** | Non-interventional |
| **Title** | PREVAIL: A Prospective, Non-Interventional Study to Assess the Prevalence of PD-L1 Expression in the First-Line Setting of Locally Advanced/Unresectable or Metastatic Urothelial Carcinoma |

*This study was not provided with a URL*

|  |  |
| --- | --- |
| **Phase** | 3 |
| **Title** | [CLINICAL PROTOCOL for the INVESTIGATION of the ProSpace™ Balloon System Pivotal Study BP-007](https://clinicaltrials.gov/ct2/show/NCT03400150?term=BP-007&draw=2&rank=1) |

Looking for more information about clinical trials? Wondering if you’re a candidate for clinical research investigations? Contact our clinical trials department directly at 000-000-0000 Or request an appointment using our easy and [convenient online form](https://centraljerseyr.wpengine.com/contact-us/request-an-appointment/).